Resources

It is a privilege to represent and serve you – this pioneering community of biotech entrepreneurs, investors and enabling services companies.

The project will focus on advancing MDX-201, an innovative ADC that links a cytotoxic payload with a first-in-class monoclonal antibody (MDX-124) that targets annexin-A1.

POLB 001 cancer immunotherapy-induced CRS patent granted in Canada, further strengthening Poolbeg's global intellectual property portfolio

BIA calls for coordinated action and a clear mandate for Health Data Research Service (HDRS) to prioritise UK value creation with health innovators and job creators, a key sector for economic growth

Stevenage Bioscience Catalyst is deeply saddened to share the news that our CEO, Dr Sally Ann Forsyth OBE, passed away at home on Saturday 2 May after a long battle with illness.

CellCentric announces oversubscribed $220 Million Series D financing to advance pivotal trials of Inobrodib in Multiple Myeloma

In this guest blog, Catherine Hsu Steve Cardosi discuss Convertible Loan Notes (CLNs).

The UK BioIndustry Association (BIA) is delighted to announce Professor Chris Molloy has taken up his role as Chief Executive Officer.

Cytospire Therapeutics announces the closing of an oversubscribed £61 million ($83 million) Series A financing.

Coulter Partners successfully led a search assignment for Laigo Bio and is pleased to announce the placement of Dr. Richard C.A. Sainson as its new Chief Scientific Officer (CSO).

BioOrbit is enabling pharmaceutical drugs to be manufactured in space at scale

In this guest blog, Asma Aslam says that rising domestic costs and strong overseas capabilities are pushing companies to subcontract abroad.

Stratosvir has received support from Cell and Gene Therapy Catapult (CGT Catapult), including investment from the Cross Catapult Investment Pilot.

It has been an extremely challenging time for biotech post COVID-19 boom, but our Q1 financing report offers hope with continued positive momentum.

UK biotech financing showed signs of recovery in the first quarter of 2026, driven by a rebound in venture capital investment.

In this blog, Ethan Almond reflects on the inaugral BioSolutions UK conference, which brought together over 200 innovators, policymakers and industry leaders alongside an additional 29 investors.

Epitopea announced that it has received approval from MHRA and the REC for its clinical trial application (CTA) for its first-in-human clinical trial (OVACT) of CryptiVax™-1001.